Table 2.
Baseline Characteristics
| Characteristic | Subcutaneous (n = 26) | Intravenous (n = 20) | P Value |
|---|---|---|---|
| Age at transplantation, median (range), yr | 62 (40-73) | 60 (39-71) | .673 |
| Gender | .855 | ||
| Male | 15 (58) | 11 (55) | |
| Female | 11 (42) | 9 (45) | |
| Disease state | .494 | ||
| AML | 15 (58) | 11 (55) | |
| MDS | 9 (35) | 5 (25) | |
| Other∗ | 2 (8) | 4 (20) | |
| Disease status at transplantation | .029 | ||
| CR | 8 (31) | 7 (35) | |
| PR | 1 (4) | 4 (20) | |
| SD | 11 (42) | 1 (5) | |
| PD | 3 (12) | 4 (20) | |
| Other† | 3 (12) | 4 (20) | |
| Prior stem cell transplantation‡ | 0 | 3 (15) | .075 |
| Sorror comorbidity score, median | 3 | 4 | .434 |
| Karnofsky performance score, median | 80 | 75 | .062 |
| ASBMT risk category | .537 | ||
| Low | 10 (38) | 7 (35) | |
| Intermediate | 3 (12) | 5 (25) | |
| High | 13 (50) | 8 (40) | |
| CMV IgG seropositive | |||
| Donor | 14 (54) | 8 (40) | .351 |
| Recipient | 17 (65) | 14 (70) | .741 |
| Graft source | <.001 | ||
| Peripheral blood | 26 (100) | 10 (50) | |
| Bone marrow | 0 | 10 (50) | |
| Days to start of GCSF, median (range) | 10 (1-12) | 10 (5-14) | .311 |
AML indicates acute myeloid leukemia; MDS, myelodysplastic syndrome; CR, complete remission; PR, partial response; SD, stable disease; PD, progressive disease; ASBMT, American Society for Blood and Marrow Transplantation; GCSF, granulocyte colony–stimulating factor.
Data presented are n (%), unless otherwise indicated.
∗
Others include follicular lymphoma, systemic mastocytosis, histiocytic sarcoma, non-Hodgkin lymphoma, myelofibrosis, and chronic neutrophilic leukemia.
†
Others include CR2, PR2.
‡
All patients previously had an autologous stem cell transplantation.